ArticleInternational journal of hematology2023

Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies.

Wataru Munakata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.